Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.

"Declarations Conflict of interestD.J. de Jong received consulting fees from Synthon, Pharma, Abbvie, and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor Pharma, and Cablon Medical. F. Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen-Cilag, MSD, Takeda, Teva, Sandoz, and Dr. Falk, and has received unrestricted grants from Dr. Falk, Janssen-Cilag, Abbvie, Takeda. Other authors have no potential conflict of interest to disclose. Ethical approvalThis study was approved by the Radboud University Medical Center Committee on Research Involving Human Subjects (2017-3656). Informed consentAll participants provided written consent. Conflict of interest D.J. de Jong received consulting fees from Synthon, Pharma, Abbvie, and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor Pharma, and Cablon Medical. F. Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen-Cilag, MSD, Takeda, Teva, Sandoz, and Dr. Falk, and has received unrestricted grants from Dr. Falk, Janssen-Cilag, Abbvie, Takeda. Other authors have no potential conflict of interest to disclose."

"Funding No funding has been received for this study."